0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > TREM-1

TREM-1

Brief Information

Name:Triggering receptor expressed on myeloid cells 1
Target Synonym:Triggering Receptor Expressed On Myeloid Cells 1,CD354 Antigen,Triggering Receptor Expressed on Myeloid Cells-1,TREM-1,TREM1,CD354,Triggering receptor expressed on monocytes 1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Nach Produktstatus:
Nach Produktkategorie :
Nach Arten:
Nach Markierungen:
Nach Konjugaten:
Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
TR1-H5251 Human Human TREM-1 / CD354 Protein, Fc Tag
TR1-H5251-structure
TR1-H5251-sds
ACRO Quality

Part of Bioactivity data

TR1-H5251-BLI
 TREM-1 BLI

Loaded Human TREM-1, Fc Tag (Cat. No. TR1-H5251) on Protein A Biosensor, can bind Recombinant Human PGLYRP1/PGRP-S Protein, CF with an affinity constant of 18.5 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

TR1-H5251-ELISA
 TREM-1 ELISA

Immobilized Human TREM-1, Fc Tag (Cat. No. TR1-H5251) at 5 μg/mL (100 μL/well) can bind Recombinant Human PGLYRP1/PGRP-S Protein, CF with a linear range of 0.002-0.156 μg/mL (Routinely tested).

Synonym Name

TREM1,CD354

Background

Triggering receptor expressed on myeloid cells 1 (TREM1) is also known as CD antigen CD354, and is a type I transmembrane protein with a single Ig-like domain. TREM1 is highly expressed in adult liver, lung and spleen than in corresponding fetal tissue. TREM-1 / CD354 stimulates neutrophil and monocyte-mediated inflammatory responses, and also triggers release of pro-inflammatory chemokines and cytokines, as well as increased surface expression of cell activation markers. Amplifier of inflammatory responses that are triggered by bacterial and fungal infections and is a crucial mediator of septic shock. TREM1 can interacts with TYROBP / DAP12.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Nangibotide LR-12 Phase 2 Clinical Inotrem Shock, Septic; Coronavirus Disease 2019 (COVID-19) Details
CEL383 CEL-383 Phase 1 Clinical Celsius Therapeutics Inc Inflammatory Bowel Diseases Details
TREM 1 antibody(Boehringer Ingelheim International Gmbh) TREM 1 antibody(Boehringer Ingelheim International Gmbh) Phase 1 Clinical Boehringer Ingelheim International Gmbh Immune System Diseases Details
PY-159 PY-159 Phase 1 Clinical Centre for the Commercialization of Antibodies and Biologics Solid tumours; Neoplasms Details
Nangibotide LR-12 Phase 2 Clinical Inotrem Shock, Septic; Coronavirus Disease 2019 (COVID-19) Details
CEL383 CEL-383 Phase 1 Clinical Celsius Therapeutics Inc Inflammatory Bowel Diseases Details
TREM 1 antibody(Boehringer Ingelheim International Gmbh) TREM 1 antibody(Boehringer Ingelheim International Gmbh) Phase 1 Clinical Boehringer Ingelheim International Gmbh Immune System Diseases Details
PY-159 PY-159 Phase 1 Clinical Centre for the Commercialization of Antibodies and Biologics Solid tumours; Neoplasms Details

This web search service is supported by Google Inc.

totop

Nachricht schicken